Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Apr 1;18(7):1824-6.
doi: 10.1158/1078-0432.CCR-12-0151. Epub 2012 Feb 21.

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib

Augusto Villanueva  1 , Josep M Llovet
Affiliations
Comment

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib

Augusto Villanueva et al. Clin Cancer Res. .

Abstract

Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting.

PubMed Disclaimer

Conflict of interest statement

Conflict of interests: AV has nothing to disclose. JML has received research support from Bayer Pharmaceuticals and Bristol Myers Squibb; and has consultancy agreements with Bayer Pharmaceuticals, Bristol Myers Squibb, Imclone and Biocompatibles.

Figures

Figure 1
Figure 1
Molecular targets and therapies in the management of patients with advanced HCC. Three approaches have already failed to meet the primary endpoint, and since there is certain degree of target overlap, it is possible that additional approaches will not succeed. New strategies should prime the development of new targets based on the identification of oncogenic addiction loops. Also, and similarly to other solid tumors, trial design for targeted therapies should consider enrichment strategies for patients with such molecular addiction events.
See this image and copyright information in PMC

Comment on

References

    1. Finn SR, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012 - PubMed
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. - PubMed
    1. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140:1410–1426. - PMC - PubMed
    1. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, et al. Phase II, open-label sutdy of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2011;17:1973–1983. - PubMed
    1. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. - PubMed

Publication types